ArticleFrontiers in immunology2026
Complement C5 inhibitor as a rescue therapy for acute NMOSD attacks: a multicenter retrospective cohort study in China.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Complement activation plays a key role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). While eculizumab effectively prevents relapses, its role in acute attacks remains uncertain. Methods: We retrospectively analyzed 38 patients with acute NMOSD treated with eculizumab across seven tertiary hospitals in China. Neurological assessments included EDSS, visual, motor, and sensory deficits, evaluated at baseline and weekly through 8 weeks. Clinical improvement was defined using prespecified criteria. Safety and adverse events were recorded. Results: Patients were predominantly female (92.1%) with a mean age of 47.5 ± 14 years. Median EDSS decreased from 4 (IQR 3-6.88) to 3 (IQR 2-6) at the 4-8-week follow-up assessment (p = 5.45 × 10 Conclusion: This exploratory study observed neurological improvement following eculizumab initiation in patients with NMOSD attacks, but serious infections can occur in severely disabled patients, highlighting the need for careful monitoring and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.